SavedAdd your journal

Journals / İstanbul Medical Journal / 2020 / Cilt: 21 - Sayı: 2

Prognostic Analysis of Neutrophil/Lymphocyte Ratio and Thrombocyte/Lymphocyte Value Before Trimodal Treatment in Invasive Bladder Cancer

İnvaziv Mesane Kanserinde Trimodal Tedavi Öncesinde Nötrofil/Lenfosit Oranı ve Trombosit/Lenfosit Değerinin Prognostik Önemi

Berrin İNANÇ
Özlem MERMUT
Pages
82–87
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the receiver operatingcharacteristic analysis, the optimum cut-off value for NLR wasfound to be 3.2 (sensitivity 71.4%, specificity 65.2% p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: To evaluate whether neutrophil/lymphocyte(NLR) and platelet/lymphocyte (PLR) ratios have prognosticvalue in patients undergoing bladder conserving treatment(trimodal therapy).Methods: A total of 40 patients receiving trimodality treatmentfor invasive bladder cancer were included in the studyretrospectively.
📊
Key Findings & Data:NLR and PLR were obtained for every patientbefore trimodality treatment was applied.
💡
Conclusion & Impact:In the receiver operatingcharacteristic analysis, the optimum cut-off value for NLR wasfound to be 3.2 (sensitivity 71.4%, specificity 65.2% p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: To evaluate whether neutrophil/lymphocyte(NLR) and platelet/lymphocyte (PLR) ratios have prognosticvalue in patients undergoing bladder conserving treatment(trimodal therapy).Methods: A total of 40 patients receiving trimodality treatmentfor invasive bladder cancer were included in the studyretrospectively. NLR and PLR were obtained for every patientbefore trimodality treatment was applied. We investigatedwhether NLR and PLR values had prognostic value for survival.Results: Gender, age, T stage, Histologic grade, radiotherapydose, NLR and PLR values were evaluated in bladder cancerpatients receiving trimodal therapy. In the receiver operatingcharacteristic analysis, the optimum cut-off value for NLR wasfound to be 3.2 (sensitivity 71.4%, specificity 65.2% p

Özet

Amaç: Mesane koruyucu tedavi (trimodal tedavi) uygulanan hastalarda nötrofil/lenfosit (NLR) ve trombosit/lenfosit (PLR) oranının prognostik bir değerinin olup olmadığını değerlendirdik. Yöntemler: Bu retrospektif çalışmaya kasa invaze mesane kanseri tanısı alan ve trimodal (TUR + kemoradyoterapi) tedavi uygulanan 40 hasta dahil edildi. Trimodal tedavi uygulanmadan önce NLR ve PLR kan değerlerinden elde edildi. NLR ve PLR değerlerinin sağkalım açısından prognostik değeri olup olmadığı araştırıldı. Bulgular: Trimodal tedavi alan mesane kanserli hastalarda, cinsiyet, yaş, T evresi, radyoterapi dozu, NLR ve PLR değerleri değerlendirildi. Alıcı işletim karakteristiği analizinde NLR için, optimum cut-off değeri 3,2 olarak bulundu. (sensitivite %71,4, spesifite %65,2 p

🔖

Cite This Article

İNANÇ, B., MERMUT, Ö. (2022). Prognostic Analysis of Neutrophil/Lymphocyte Ratio and Thrombocyte/Lymphocyte Value Before Trimodal Treatment in Invasive Bladder Cancer. İstanbul Medical Journal, Cilt: 21 - Sayı: 2, 82–87. https://ajindex.com/articles/551870

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Solsona E, Iborra I, Collado A, Rubio-Briones J, Casanova J, Calatrava A. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 2010; 184: 475-80
  2. Leibovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, et al. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 2007; 70: 473-6
  3. Herszényi L, Lakatos G, Hritz I, Varga M.Z, Cierny G,Tulassay Z. The role of inflam mation and proteinases in tumor progression. Dig Dis 2012; 30: 249- 54
  4. Jaramillo-Reta KY, Velázquez-Dohorn ME, Medina-Franco H. Neutrophil to lymphocyte ratio as predictor of surgi- cal mortality and survival in complex surgery of the upper gas- trointestinal tract. Rev Invest Clin 2015; 67: 117-21
  5. Cho H, Hur HW, Kim SW,Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009; 58: 15- 23
  6. Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, et al. Neutrophil –to- lymphocyte ratio predicts progression and recurrence of non- muscleinvasive bladder cancer. Urol Oncol 2015; 33: 67.e1-7
  7. Krane LS, Richards KA, Kader AK, Davis R, Balaji KC, Hemal AK. Preopera- tive neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystec- tomy. J Endourol 2013; 27: 1046-50
  8. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10– 30 9. Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004; 22: 86–92
  9. Mak RH, Zietman AL, Heney NM, Kaufman DS, Shipley WU. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008; 102: 1345-53
  10. Totterman TH, Loskog A, Essand M: The immunotherapy of prostate and bladder can- cer. BJU Int 2005; 96: 728–35
  11. Yamada H, Luo Y, Matsumoto T, O’Donnel M. A novel expression of macrophage derived chemo- kine in human bladder cancer. J Urol 2005; 173: 990–5
  12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer related inflammation. Nature 2008; 454: 436–44 14. O’Toole C, Perlman P, Unsgaard B, Moberger G, Edsmyr F. Celllular immunity to human urinary bladder carcinoma. Correlation to clinical stage and radiotherapy. Int J Cancer 1972; 10: 77–91
  13. Motomura T, Shirabe K, Mano Y, Muto J, T